Table II.
Pharmacokinetic Parameters of C2E3 and C2E2 After Application of Neat C2E5 Oil or 40% C2E5 Nonaqueous gel at a C2E5 Dose of 200 mg/kg (n = 4) and the Enhancement Ratio of C2E3 and C2E2 Based on the Formula AUC0–24 h (C2E5 gel)/AUC0–24 h (neat C2E5)
| C2E3 | C2E2 | |||||||
|---|---|---|---|---|---|---|---|---|
| Treatment | Cmax (mean ± SD, μg/mL) | Tmax (mean ± SD, h) | AUC0-24h (mean ± SD, h × μg/mL) | Enhancement ratio (AUC0–24 h (C2E5 gel)/AUC0–24 h (neat C2E5)) | Cmax (mean ± SD, μg/mL) | Tmax (mean ± SD, h) | AUC0-24h (mean ± SD, h × μg/mL) | Enhancement ratio [AUC0–24 h (C2E5 gel)/AUC0–24 h (neat C2E5)] |
| Neat C2E5 oil at 200 mg/kg | 0.181 ± 0.097 | 9.6 ± 10.9 | 1.21 ± 0.16 | 2.9 | 0.059 ± 0.041 | 17.0 ± 8.2 | 0.660 ± 0.351 | 4.2 |
| 40% C2E5 nonaqueous gel at 200 mg/kg | 0.281 ± 0.159 | 4.5 ± 4.0 | 3.52 ± 2.26 | 0.203 ± 0.161 | 4.5 ± 2.5 | 2.75 ± 1.89 | ||
C max maximum plasma concentration during 0–24 h period, T max time of maximum plasma concentration during 0–24 h period, AUC 0–24 h area under the curve during 0–24 h period